EyePoint’s 120% Surge Raises the Question: Is It Still a Buy or a Bubble?
EyePoint Pharmaceuticals (NASDAQ: EYPT) has been on a wild ride. Over the past 12 months, the stock surged more than 120%, closing at US$13.75. But the picture gets more complicated when you zoom in: it’s down 21.3% year-to-date, and over the last month it’s barely budged, up just 2.6%. For investors watching from the sidelines—or those already holding—the big question is whether the current price reflects genuine value or just hype.
According to a discounted cash flow (DCF) analysis by Simply Wall St, EyePoint’s intrinsic value sits around US$76.55 per share. That’s roughly 82% above the current trading price. On paper, that screams “undervalued.” But the DCF model relies on projections that show the company burning cash for several more years before turning profitable—expected to hit positive free cash flow of about US$100.5 million by 2030. That’s a long runway, and in biotech, timelines can shift dramatically.
On the other side of the coin, EyePoint’s price-to-sales (P/S) ratio tells a very different story. At 36.7x, it towers over the pharmaceuticals industry average of 5.5x and the peer group average of 5.9x. Simply Wall St’s own “Fair Ratio” for EyePoint—adjusted for its growth rate, margins, and risk profile—comes in at 0.0x, suggesting the market is pricing in far more optimism than the fundamentals currently support.
So which is it—deeply undervalued or dangerously overvalued? The answer may depend on which narrative you buy into.
On the Simply Wall St community platform, investors have been building out their own scenarios. One bullish narrative, built around aggressive revenue growth and successful clinical milestones, supports a fair value near US$59.30. A more cautious take, factoring in trial delays and competitive pressure, lands closer to US$20.00. The gap between those two numbers is a reminder of just how binary biotech investing can be.
We reached out to a few investors following the stock. Mark Chen, a retail investor from Austin, Texas, said: “I’ve been holding EYPT for about 18 months. The DCF numbers are compelling, but I’m not naive—this is a binary bet on clinical data. If the next trial reads positive, we could see US$50. If it fails, we’re looking at single digits. I’m staying in, but I’ve trimmed my position.”
Linda Torres, a biotech analyst based in San Francisco, offered a more measured take: “The P/S ratio is a red flag for anyone who thinks this is a value play. EyePoint is still pre-commercial in its core pipeline. The market is pricing in a lot of future success that hasn’t been de-risked yet. I’d wait for clearer catalysts before adding exposure.”
And then there’s David Ortiz, a former pharma executive turned private investor, who didn’t hold back: “This stock is a casino. 36x sales for a company that’s still losing a quarter of a billion dollars a year? Come on. The DCF model is a fantasy until they prove they can actually commercialize something. I shorted it last month and I’m not losing sleep.”
For context, EyePoint is developing sustained-release drug delivery systems for eye diseases, including its lead candidate for wet age-related macular degeneration. The space is crowded—competitors include Regeneron, Roche, and a host of smaller biotechs. Any delay or negative readout could send the stock reeling.
Ultimately, EyePoint sits at the intersection of two very different valuation stories. The DCF says it’s a bargain. The P/S says it’s priced for perfection. Which one you trust may come down to your timeline, your risk tolerance, and your view on whether the company can deliver on its promise.
This article is for informational purposes only and does not constitute financial advice. Always do your own research before making investment decisions.